Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Phase 2

Terminated

Conditions: Acne Vulgaris

Interventions: Drug: BMX-010 0.3%

Registration Number: NCT03752242

Lead Sponsor: BioMimetix JV, LLC

Brief Summary: This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts.

Detailed Description: Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug in patients with Acne. Up to 60 subjects will be enrolled in this part.

Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo in patients with Acne. Up to 150 subjects will be enrolled in this part. In both parts, adult subjects with Acne will be enrolled.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 2

Inclusion Criteria

Male or female, at least 18 years of age;
A clinical diagnosis of mild to severe facial Acne Vulgaris; Subjects may also have acne at other body sites;
Screening and Baseline IGA score > 2 (greater than or equal to 2);
Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
Candidate for topical treatment of Acne;
If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
Ability to understand and provide written informed consent.

Exclusion Criteria

Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
Use of androgen receptor blockers (such as spironolactone or flutamide);
Severe cystic acne, acne conglobate, acne fulminans, or secondary acne;
Use of phototherapy devices, energy-based devices, adhesive cleansing strips, or cosmetic procedures (e.g., facials, peeling, comedo extraction) in the past week;
Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
Prior or current concomitant therapies that would interfere with assessments in the study;
Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [e.g., benzamycin]), retinoids; other topical acne treatments (e.g., photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks;
Oral retinoid use (e.g., isotretinoin) within 6 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline;
Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
Use of medicated make-up (including anti-aging make-up) throughout the study;
Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact acne, 4) immunosuppressive agents, or immunomodulators;
Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical acne treatments or 4) topical antibiotics;
Use of medicated cleansers on the face (throughout the study);
Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
Systemic or skin infection requiring antimicrobial therapy;
Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
Active drug or alcohol dependence;
Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
Previous clinical trial participation for the indication being treated in this protocol.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BMX-010 0.03%	BMX-010 0.3%	Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.

Primary Outcome Measures

Name	Time	Method
Determine Whether the Optimum Frequency of Topical Application of BMX-010 0.03% is Once a Day or Twice a Day Day or Twice Per Day for a Treatment Interval of 7 to 28 Days.	28 days	Assessed by change in the 5-point Investigator Global Assessment (IGA), compared amongst the group that is treated once a day versus twice a day. This will be measured weekly from Days 1-28. The Investigator global assessment scale is a global assessment of disease as the time of evaluation. The lowest number on the scale (0) is clear from disease while the highest number (4) is severe disease. Scores on the scale are: 0, 1, 2, 3, 4
Evaluate the Efficacy of BMX-010 in Treatment of Acne Vulgaris.	43 days	Assessed by change in the 5-point Investigator Global Assessment (IGA). This will be measured weekly from Days 1-28, followed by a final assessment two weeks after dosing ends at day 43. Assessed by change in the 5-point Investigator Global Assessment (IGA), compared amongst the group that is treated with study drug versus with placebo. This will be measured weekly from Days 1-28. The Investigator global assessment scale is a global assessment of disease as the time of evaluation. The lowest number on the scale (0) is clear from disease while the highest number (4) is severe disease. Scores on the scale are: 0, 1, 2, 3, 4

Secondary Outcome Measures

Name	Time	Method
Assess the Mean Percent Reduction Change in Inflammatory Lesion Counts From Baseline to End of Study.	43 days	Inflammatory lesions will be counted at each study visit and the total change in the count of lesions will be assessed from baseline to day 43.
Assess the Mean Percent Reduction Change in Noninflammatory Lesion Counts From Baseline to End of Study.	43 days	Non-Inflammatory lesions will be counted at each study visit.